ArticleCellular and molecular neurobiology2015
Altered Expression of Intersectin1-L in Patients with Refractory Epilepsy and in Experimental Epileptic Rats.
Article in Cellular and molecular neurobiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MicroRNAs Regulating Cytoskeleton Dynamics, Endocytosis, and Cell Motility-A Link Between Neurodegeneration and Cancer?Frontiers in neurology · 2020Review
- Abnormal Expression of FBXL20 in Refractory Epilepsy Patients and a Pilocarpine-Induced Rat Model.Neurochemical research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is a common neurological disorder. Because its underlying mechanisms remain incompletely understood, current treatments are not adequate for all epilepsy patients, and some patients progress to refractory epilepsy. Under physiological conditions, excitatory and inhibitory neurons function in a dynamic balance. Epilepsy develops when this balance is disrupted. Intersectin1-L is a major scaffold protein in the central nervous system that contains multiple functional domains, and it is the long form of intersectin1. Recent studies have shown that intersectin1-L plays an important role in the process of neurotransmitter release. In this study, we investigated the expression pattern and distribution of intersectin1-L in patients with refractory epilepsy, in a rat model of pilocarpine-induced epilepsy, and in a rat model of amygdala-kindled epilepsy by immunohistochemistry, immunofluorescence, and Western blotting. The purpose of this study was to explore the relationship between epilepsy and intersectin1-L. The results showed that the intersectin1-L protein was primarily expressed in neurons in brain tissue. Its expression was remarkably increased in patients with refractory epilepsy and in epilepsy model rats. These results suggest that the abnormal expression of the intersectin1-L protein in epileptic brain tissue may play an important role in epilepsy, especially refractory epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.